最新发布

What China’s new CGT rules mean for biotech business 

China’s new framework for advanced biomedical technologies could reshape how cell and gene therapies (CGTs) reach patients in one of the world’s most active biotech markets. State Council Order No. 818 took effect on May 1, 2026, and establishes China’s first national framework for the clinical research and translational application of new biomedical technologies, including cell therapies, gene therapies, gene editing, stem cell technologies, tissue engineering, and other emerging medical approaches.  

ASCO: Immatics posts data on PRAME pipeline ahead of pivotal readout

The biotech, which has a presence in Germany and Texas, has built a pipeline on preferentially expressed antigen in melanoma (PRAME). The cancer-testis antigen is broadly expressed in solid tumors, providing Immatics with chances to treat a range of diseases including cutaneous melanoma, uterine carcinoma and synovial sarcoma.

Spraying with autonomous Prospr

“Specialty crop growers are looking for practical, scalable automation technologies that can help them be more sustainable, efficient and profitable today, while also preparing for the future”, says Yamaha Agriculture President and CEO Nolan Paul.

Amyris CEO on the post-bankruptcy re-boot: ‘We’re a drastically different company’

Two years after emerging from bankruptcy, biomanufacturing specialist Amyris is not yet profitable, but is a “drasticall…

Oculis drops plans for diabetic macular edema drug after Phase III miss

The Zug-based company said the DIAMOND-1 and DIAMOND-2 trials did not show a statistically meaningful improvement in best corrected visual acuity after 52 weeks of treatment compared with vehicle. The result is particularly damaging because visual acuity was the primary endpoint of the programme and the basis for a potential regulatory filing.

Neuropixels Opto Integrates Electrophysiology and Optogenetics to Probe Neuronal Function

High-resolution extracellular electrophysiology is typically used to record from neurons in order to understand brain function. Combining electrophysiology with optogenetics allows researchers to test the causal role of specific neurons by activating or inactivating those populations while recording the effects of neural activity.

Servier buys Edgewise muscular dystrophy business for up to US$2.65bn

Under the agreement, Servier will pay US$1.55bn upfront and up to US$1.1bn in regulatory and commercial milestones. The transaction, unanimously approved by the boards of both companies, is expected to close in the third quarter of 2026.

RNA生物农药产业化窗口正在打开——这是中国农化企业布局新赛道的入场时机吗?

全球农药市场正在发生一场深层转变:法规收紧、传统活性成分加速退出、绿色植保需求持续升温——化学农药企业面临的压力有目共睹。与此同时,RNA生物农药这一被誉为继化学农药、微生物农药之后最具潜力的新一代植保技术,正在全球范围内从"实验室概念"加速走向真实产品。中国创新力量深度参与其中,并正在带着可落地的产业化成果走向行业视野。

Macrocyclic Peptide Drugs Unlocked, Membrane Permeability Screened at Scale

Macrocyclic peptides are a promising drug modality that  combine the   oral convenience of small molecules with the high specificity of large biologics. Yet, they struggle with cell membrane permeability, limiting their ability to target disease interactions within cells.   

T-CURX buys Pantherna as the race for in vivo CAR-T gathers pace

With this merger, there is no need to chase down the financial volume with investigative zeal and try to determine what order of magnitude the deal might fall into. That is not what matters here. At first glance, the acquisition may look like a relatively small merger between two smaller German biotech companies, and the casual reader may simply move on. Behind it, however, lies a strategic trend that is currently preoccupying the cell therapy industry: the development of so-called in vivo CAR-T therapies.